Abstracts Archive - Page 1997 of 2425 - ACR Meeting Abstracts

Abstract Number: 834 • 2014 ACR/ARHP Annual Meeting
Interleukin-18 (IL-18) As a Biomarker for Diagnosis and Evaluation of Disease Activity in Patients with Adult Onset Still’s Disease and Systemic Onset Juvenile Idiopathic Arthritis
Holger Kudela¹, Susanne Drynda², Anke Lux³, Gerd Horneff⁴ and Joern Kekow², ¹Univ of Magdeburg, Clinic for Rheumatology, Vogelsang-Gommern, Germany, ²Clinic of Rheumatology, Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany, ³Univ of Magdeburg, Institute for Biometry and Medical Informatics, Magdeburg, Germany, ⁴Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: Establishing the diagnosis of adult onset Still’s disease (AOSD) as well as of systemic onset juvenile idiopathic arthritis (sJIA) is very challenging. Mostly it…
Abstract Number: 833 • 2014 ACR/ARHP Annual Meeting
Canakinumab Use in Patients with Cryopyrin-Associated Periodic Syndrome: Interim Safety and Efficacy Results from Beta-Confident Registry
Hal M. Hoffman¹, Jasmin B. Kuemmerle-Deschner², Philip N. Hawkins³, T. van der Poll⁴, Ulrich A. Walker⁵, Ken Abrams⁶ and Hugh H. Tilson⁷, ¹Division of Allergy, Immunology and Rheumatology, University of California at San Diego, La Jolla, CA, ²University Hospital Tuebingen, Tuebingen, Germany, ³University College London Medical School, London, United Kingdom, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ⁶Novartis Pharmaceutical Corporation, East Hanover, NJ, ⁷Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC
Background/Purpose The three phenotypes in the order of severity: familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic infantile neurologic cutaneous and articular syndrome/neonatal…
Abstract Number: 832 • 2014 ACR/ARHP Annual Meeting
NOD2-Associated Autoinflammatory Disease: The Largest Cohort Study
Qingping Yao¹, Min Shen², Christine McDonald³, Felicitas Lacbawan⁴ and Bo Shen⁵, ¹Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH, ²Rheumatic and Immunologic Disease, Cleveland Clinic, Cleveland, OH, ³Pathobiology, Cleveland Clinic, Cleveland, OH, ⁴Molecular Genetics Pathology, Cleveland Clinic, Cleveland, OH, ⁵Gastroenterology, Cleveland Clinic, Cleveland, OH
Background/Purpose NOD2-associated autoinflammatory disease (NAID) is an emerging systemic inflammatory disease. The aim is to report our extended study of the phenotypic and genotypic features of…
Abstract Number: 811 • 2014 ACR/ARHP Annual Meeting
Biologics in Takayasu Arteritis: Preliminary Data from the French Registry
Arsene Mekinian¹, Chloe Comarmond², Mathieu Resche Regon³, Tristan Mirault⁴, Jean-Emmanuel Kahn⁵, Marc Lambert⁶, Jean Sibilia⁷, Antoine Neel⁸, Miguel Hié⁹, Emmanuel Messas¹⁰, Pascal Cohen¹¹, Geraldine Muller¹², Sabine Berthier¹³, Zahir Amoura¹⁴, Isabelle Marie¹⁵, Christian Lavigne¹⁶, Marie Anne Vandenhende¹⁷, Hervé Devilliers¹⁸, Sébastien Abad¹⁹, Loic Guillevin²⁰, Mohamed Hamidou²¹, Bertrand Godeau²², Patrice Cacoub²³, Olivier Fain²⁴ and David Saadoun², ¹DHU2iB, Internal Medicine Saint Antoine Hospital, PARIS, France, ²DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ³biostatistics Saint Louis Hospital, paris, France, ⁴HEGP vascular department, paris, France, ⁵Internal Medicine, Foch Hospital, Suresnes, France, ⁶Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ⁷Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ⁸INTERNAL MEDICINE, NANTES, France, ⁹Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ¹⁰HEGP hospital Vascular and cardiology Department, paris, France, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹²INTERNAL MEDICINE, DIJON, France, ¹³DIJON HOSPITAL, DIJON, France, ¹⁴Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ¹⁵CHU de Rouen, Rouen, France, ¹⁶CHU d'Angers, Angers, France, ¹⁷Internal Medicine, Bordeaux, France, ¹⁸Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ¹⁹Hôpital Avicenne, Bobigny, France, ²⁰Internal Medicine, Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France, ²¹CHU Hôtel Dieu, Nantes, Nantes, France, ²²Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, ²³Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ²⁴Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France
Background/Purpose The aim of this registry is to determine: (1) the real-life use of various biological targeted treatments in Takayasu arteritis (TA) in France; (2)…
Abstract Number: 810 • 2014 ACR/ARHP Annual Meeting
Damage Assessment in Takyasu Arteritis Using Takayasu Arteritis Damage Score (TADS)
Debashish Danda¹, Ruchika Goel², Raheesh Ravindran² and George Joseph³, ¹Clinical Immunology& Rheum, Christian Medical College, Vellore Tamilnadu, India, ²Clinical Immunology & Rheumatology, Christian Medical College & Hospital, Vellore, India, Vellore, India, ³Cardiology, Christian Medical College & Hospital, Vellore, India, Vellore, India
Background/Purpose Takayasu arteritis (TA) is a prototype large vessel vasculitis. Assessment of disease activity and damage has been challenging in TA due to lack of…
Abstract Number: 809 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Severe Ischemic Complications in Takayasu Arteritis: A French Multicenter Retrospective Cohort of 182 Patients
Cloé Comarmond¹, Tristan Mirault², Jean-Emmanuel Kahn³, Philippe Cluzel⁴, Fabien Koskas⁵, Laurent Chiche⁶, Julien Gaudric⁷, Emmanuel Messas⁸, Patrice Cacoub⁹ and David Saadoun¹⁰, ¹Internal Medicine and Clinical Imunology, Referal Center for Autoimmune diseases, Internal Medicine and Clinical Imunology, Hôpital Pitié Salpétrière, Paris, France, ²HEGP vascular department, paris, France, ³Internal Medicine, Foch Hospital, Suresnes, France, ⁴Vascular and Interventional Imaging Department, Paris, France, ⁵Vascular Surgery, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁶Vascular Surgery, Paris, France, ⁷Department of Vascular surgery GHPS, Paris, France, ⁸Vascular Department, Paris, France, ⁹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ¹⁰DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France
Background/Purpose .Takayasu arteritis (TA) is a chronic inflammatory disease that primarily affects large vessels, such as the aorta and its main branches. To report clinical…
Abstract Number: 808 • 2014 ACR/ARHP Annual Meeting
Biomarkers of Disease Activity in Vasculitis
Alicia Rodriguez-Pla¹, Roscoe L. Warner², David Cuthbertson³, Simon Carette⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, Curry L Koening⁷, Carol A. Langford⁸, Kathleen Maksimowicz-McKinnon⁹, Larry W. Moreland¹⁰, Christian Pagnoux⁴, Philip Seo¹¹, Ulrich Specks^12,13, Kenneth J. Warrington¹⁴, Steven R. Ytterberg¹⁵, Peter A. Merkel¹⁶, Kent J. Johnson², Paul A. Monach¹⁷ and For the Vasculitis Research Consortium¹⁸, ¹Rheumatology, Boston University, Boston, MA, ²Pathology, University of Michigan, Ann Arbor, MI, ³Department of Biostatistics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁶Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁸Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁹Rheumatology, Henry Ford Hospital, Detroit, MI, ¹⁰Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Frederichs Dr NW, Mayo Clinic, Rochester, MN, ¹³Mayo Clinic, Rochester, MN, ¹⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁶University of Pennsylvania, Philadelphia, PA, ¹⁷Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ¹⁸U Pennsylvania, Philadelphia, PA
Background/Purpose To identify circulating proteins that distinguish between active vasculitis and remission in giant cell arteritis (GCA), Takayasu's arteritis (TAK), polyarteritis nodosa (PAN) and eosinophilic…
Abstract Number: 807 • 2014 ACR/ARHP Annual Meeting
Serum Cytokine Profiles in Takayasu’s Arteritis: A Search for a Biomarker
Fatma Alibaz-Oner¹, P.Sibel Yentür², Guher Saruhan-Direskeneli³ and Haner Direskeneli¹, ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Physiology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey, ³Department of Physiology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Assessment of disease activity is one of the main difficulties in patients with Takayasu Arteritis (TAK) during follow-up. In this study, we aimed to…
Abstract Number: 806 • 2014 ACR/ARHP Annual Meeting
Association of a Single Nucleotide Polymorphism (SNP) in IL-12B Region with Clinical Features and Peripheral T Cell Profiles of Patients with Takayasu Arteritis
Toshiki Nakajima¹, Hajime Yoshifuji¹, Chikashi Terao², Koji Kitagori¹, Ran Nakashima¹, Yoshitaka Imura³, Naoichiro Yukawa¹, Koichiro Ohmura¹, Takao Fujii¹ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Center for Genomic Medicine, Kyoto University, Kyoto, Japan, ³Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose We preliminarily found a SNP (A vs. C, rs6871626)　in IL-12B region　as a susceptibility gene to Takayasu arteritis (TAK) by genome-wide association study. IL-12Bencodes IL-12/IL-23…
Abstract Number: 805 • 2014 ACR/ARHP Annual Meeting
Takayasu Arteritis and Ulcerative Colitis –High Concurrence Ratio and Genetic Overlap
Chikashi Terao¹, Takayoshi Matsumura², Hajime Yoshifuji³, Yohei Kirino⁴, Yasuhiro Maejima⁵, Yoshikazu Nakaoka⁶, Meiko Takahashi¹, Eisuke Amiya², Natsuko Tamura⁵, Toshiki Nakajima³, Tomoki Origuchi⁷, Tetsuya Horita⁸, Mitsuru Matsukura², Yuta Kochi², Akiyoshi Ogimoto⁹, Motohisa Yamamoto¹⁰, Hiroki Takahashi¹¹, Shingo Nakayamada¹², Kazuyoshi Saito¹², Yoko Wada¹³, Ichiei Narita¹³, Yasushi Kawaguchi¹⁴, Hisashi Yamanaka¹⁴, Koichiro Ohmura³, Tatsuya Atsumi⁸, Kazuo Tanemoto¹⁵, Tetsuro Miyata², Masataka Kuwana¹⁶, Issei Komuro², Yasuharu Tabara¹, Atsuhisa Ueda¹⁷, Mitsuaki Isobe¹⁸, Tsuneyo Mimori³ and Fumihiko Matsuda¹, ¹Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Tokyo Medical and Dental University, Tokyo, Japan, ⁶Osaka University Graduate School of Medicine, Osaka, Japan, ⁷Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁸Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁹Ehime University Graduate School of Medicine, Ehime, Japan, ¹⁰Sapporo Medical University School of Medicine, Sapporo, Japan, ¹¹First Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan, ¹²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹³Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ¹⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁵Kawasaki Medical School, Kurashiki, Japan, ¹⁶Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁷Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ¹⁸Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose . Takayasu arteritis (TAK) is a systemic vasculitis affecting large arteries and large branches of the aorta. Ulcerative colitis (UC) is a prevalent autoimmune…
Abstract Number: 804 • 2014 ACR/ARHP Annual Meeting
Vasculitis and Inflammatory Bowel Diseases: A Study of 32 Patients with Both Conditions and Systematic Review of the Literature
Alice Sy¹, Natasha Dehghan², Nader A. Khalidi³, Lillian Barra⁴, Simon Carette⁵, David Cuthbertson⁶, Gary S. Hoffman⁷, Curry L Koening⁸, Carol A. Langford⁹, Carol McAlear¹⁰, Paul A. Monach¹¹, Larry W. Moreland¹², Philip Seo¹³, Ulrich Specks¹⁴, Steven R. Ytterberg¹⁵, Gert Van Assche¹⁶, Peter A. Merkel¹⁰ and Christian Pagnoux⁵, ¹Medicine Division, London, ON, Canada, ²Rheumatology Division, Vancouver, BC, Canada, ³Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, St. Joseph's Health Care, London, ON, Canada, ⁵Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁶Department of Biostatistics, University of South Florida, Tampa, FL, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁹Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Rheumatology, Boston University, Boston, MA, ¹²Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹³Johns Hopkins Vasculitis Center, Rheumatology Division, Johns Hopkins University, Baltimore, MD, ¹⁴Mayo Clinic, Rochester, MN, ¹⁵Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁶Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Small case series suggested that vasculitis and inflammatory bowel disease (IBD; Crohn’s disease [CD] or ulcerative colitis [UC]) can co-occur more commonly than the…
Abstract Number: 803 • 2014 ACR/ARHP Annual Meeting
Corticosteroid-Related Adverse Events in Patients with Giant Cell Arteritis: A Claims-Based Analysis
Gordon H. Sun¹, Khaled Sarsour², Eunice Chang¹, Michael S. Broder¹, Neil Collinson³, Katie Tuckwell³, Pavel Napalkov² and Micki Klearman², ¹Partnership for Health Analytic Research, LLC, Beverly Hills, CA, ²Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, ³Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose Giant cell arteritis (GCA) is an inflammatory vasculitis preferentially affecting large and medium-sized arteries with an incidence of 1 to 30/100,000. High-dose oral corticosteroids…
Abstract Number: 802 • 2014 ACR/ARHP Annual Meeting
Inpatient Complications in Patients with Giant Cell Arteritis: Increased Risk of Thromboembolism, Delirium and Adrenal Insufficiency
Sebastian Unizony¹, Mariano Menendez², Naina Rastalsky³ and John H. Stone¹, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose The morbidity and mortality of hospitalized giant cell arteritis (GCA) patients has been largely unexplored. The aim of this study was to analyze inpatient…
Abstract Number: 801 • 2014 ACR/ARHP Annual Meeting
Venothromboembolism in Large Vessel Vasculitis
Sankalp V. Bhavsar¹, Nader A. Khalidi², Simon Carette³, David Cuthbertson⁴, Peter C. Grayson⁵, Gary S. Hoffman⁶, Curry L. Koening⁷, Carol A. Langford⁸, Carol McAlear⁹, Larry Moreland¹⁰, Paul A. Monach¹¹, Christian Pagnoux³, Philip Seo¹², Kenneth J. Warrington¹³, Steven R. Ytterberg¹³ and Peter A. Merkel¹⁴, ¹Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Department of Biostatistics, University of South Florida, Tampa, FL, ⁵NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ⁶Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁷Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁸Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁹Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ¹⁰Vasculitis Center, of University of Pittsburgh Medical Center, Pittsburgh, PA, ¹¹Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ¹²Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹³Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Venous thromboembolic disease (VTE) is a recognized characteristic of various systemic vasculitides, particularly small-vessel vasculitis. However, there are no reports describing the frequency of…
Abstract Number: 819 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a 52-Week Phase 3 Randomized Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing
Dominique L. Baeten¹, Juergen Braun², Xenofon Baraliakos³, Joachim Sieper⁴, Maxime Dougados⁵, Paul Emery⁶, Atul A. Deodhar⁷, Brian Porter⁸, Ruvie Martin⁸, Shephard Mpofu⁹ and Hanno Richards¹⁰, ¹Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁶University of Leeds, Leeds, United Kingdom, ⁷Oregon Health and Sciences University, Portland, OR, ⁸Novartis Pharma AG, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland
Background/Purpose A phase 2, proof-of-concept study indicated that secukinumab, an anti–IL-17A monoclonal antibody, suppressed signs and symptoms of active ankylosing spondylitis (AS) by Week (Wk)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].